Last reviewed · How we verify
indometacin
At a glance
| Generic name | indometacin |
|---|---|
| Also known as | Indometacin [Actavis], convention + indometacin |
| Sponsor | Maastricht University Medical Center |
| Target | Aldo-keto reductase family 1 member C4, Dehydrogenase/reductase SDR family member 9, Nicotinate phosphoribosyltransferase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Ankylosing spondylitis
- Bursitis
- Bursitis of shoulder
- Gout
- Osteoarthritis
- Patent ductus arteriosus
- Rheumatoid arthritis
- Shoulder Tendonitis
- Synovitis
- Tendinitis
- Tenosynovitis
Common side effects
Key clinical trials
- Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial (PHASE1)
- Prophylactic PS Placement to Prevent Pancreatitis After Endoscopic Transpapillary GPC for Cholelithiasis With Concomitant Choledocholithiasis (NA)
- Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement (PHASE2)
- Study Comparing Transobturator Cystocele vs. Anterior Vaginal RepairS (NA)
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Rectal Indomethacin vs Intravenous Ketorolac (PHASE4)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- indometacin CI brief — competitive landscape report
- indometacin updates RSS · CI watch RSS
- Maastricht University Medical Center portfolio CI